Traws Pharma shares rise 20.66% intraday after completing Phase 2 study showing ratutrelvir’s efficacy vs. PAXLOVID with fewer adverse events and no viral rebound.

Traws Pharma surged 20.66% intraday following the completion of its Phase 2 ratutrelvir study for oral COVID-19 treatment, which showed fewer adverse events and no viral rebounds compared to PAXLOVID. The study, enrolling 90 patients, highlighted ratutrelvir’s potential as a ritonavir-free alternative, addressing drug-drug interaction limitations of existing therapies. The company also announced plans for a 2026 human challenge study of tivoxavir marboxil, a once-monthly flu prophylactic offering 28-day protection. These developments, emphasizing clinical differentiation and expanded therapeutic applications, drove immediate investor optimism.